Suven Life sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a nAChRs antagonist for MDD
SUVEN-D4010 Phase 1 clinical trial completed successfully in USA.
Suvenís Pashamylaram unit successfully completed US FDA inspection.
Suven Life Sciences bags Pharmexcil's "Gold Patent Award"
SUVN≠502 - Completed phase 1b clinical trial under US-IND.
SUVN≠G3031 - Completed SAD and MAD studies of phase 1 clinical trial under US≠IND
SUVN-D4010 Ė IND filed in USA
Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations
SUVN-D4010 for Cognition in Alzheimerís disease commenced Phase 1 Clinical Trial in USA under US-IND126099
Suven has created a wholly owned subsidiary, Suven, Inc., a Delaware Company in USA
Suven initiates Phase 2A trial of SUVN-502 in USA
Suven Life Sciences awarded Forbes Asia's "Best Under A Billion" Award
Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” for NCE’s and “Outstanding Export Performance Award” for Contract Research and Manufacturing.
SUVEN’S PASHAMYLARAM’S UNIT RECEIVES US FDA ACCEPTANCE
Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award”
Suven to Present at Alzheimer's Association International Conference (AAIC)
Suven Life Sciences bags Pharmexcil’s Gold “Patent Award”
Suven Participating at 4th CNS Partnering & Deal Making Conference in USA
Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011”
Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011
Suven Life Sciences bags Pharmexcil's Gold “Patent Award”
Suven Life Sciences presenting at International Conference on Alzheimer’s Disease (ICAD)
Suven’s partnering and fundraising activity at C21 BioVentures
Suven achieves 1st Milestone payment in Drug Discovery collaboration
SUVEN’S UNIT- I RECEIVES US FDA ACCEPTANCE.
Suven participation at Biotech Showcase 2009.
Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride
Suven Establishes second CNS Drug Discovery Collaboration with Lilly
Suven obtains 1st Product Patent from US Patent office
Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection
Suven Unit III cGMP facility accepted by USFDA for manufacture of API's
All the units got Certification for ISO 9001 , ISO 14001, OHSAS 18001
Suven Awarded Phase III Clinical study for Chronic Low Back pain.
Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan
Gets ISO 14001:1996 certification for Unit - 1 (Suryapet) and Unit - 2 (Jeedimetla)
Name changed to Suven Life Sciences Limited
Acquired assets of New Jersey, USA based Synthon Chiragenics Corporation
cGMP Lab at SRC commissioned
Borregaard takes equity stake
Recognition of SRC as in-house R & D unit by Department of Scientific & Industrial Research (DSIR), India
New Suven Research Center (SRC) inaugurated at Hyderabad
Acquired a Drug Unit at Hyderabad, converted into Research center and Pilot Plant
ISO 9002 Certification
First sale from 'CRAMS'
Went Public (IPO)
Initiation of 'CRAMS' business model (Contract Research And Manufacturing Services)
Commenced export of Fine Chemical Intermediates
Expanded into Fine Chemical Intermediates
Incorporation as Suven Pharmaceuticals Pvt. Ltd.